Telehealth in the US for patients with end-stage kidney disease: its utilization and impact on social, economic and health outcomes

美国终末期肾病患者的远程医疗:其应用及对社会、经济和健康结果的影响

阅读:1

Abstract

The use of telehealth in the United States accelerated in 2020 when a coronavirus disease of 2019 (COVID-19) related public health emergency (PHE) was declared. Centers for Medicare and Medicaid Services issued emergency waivers that relaxed restrictions imposed by regulations on geographic locations, originating and distant sites, audio-video-conferencing technology and re-imbursement. This review focuses on the history of telehealth usage for patients with end-stage kidney disease. Patients who receive home dialysis gained widespread access to telehealth in 2019, following passage of the Bipartisan Budget Act of 2018, Sec 50302 by the US Congress. For the first time in telehealth application, the patient's home could be an originating site without geographic restrictions for telemedicine. These earlier regulations will continue even after the PHE expires. While they made telemedicine possible for many patients receiving home dialysis, in practice, the uptake of telemedicine in the home setting may have been sluggish following the 2018 law. Rules governing the frequency of telemedicine visits and other stipulations for home dialysis that were specified in the 2018 law were relaxed in the setting of the COVID-19 waivers, further facilitating the use of telemedicine for home dialysis care. Meanwhile, the in-center dialysis unit became an originating site for the first time during the COVID-19 PHE, with a corresponding sharp increase in the use of telemedicine for in-center hemodialysis care. The waivers enabling the use of telemedicine for patients who receive in-center hemodialysis and further facilitating the use of telemedicine in home dialysis, expire with the end of the COVID-19 PHE unless Congress passes new legislation. Comparisons among the periods before, during and after the PHE can illustrate telehealth's impact and some of its challenges. Most of the literature on telehealth represents observational data. Future studies on telehealth, including clinical trials, could provide information on outcomes and cost savings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。